MORRISVILLE — Robotic surgical device company TransEnterix Inc. saw its shares rise by nearly 9 percent on Tuesday after the U.S. Food and Drug Administration approved its Senhance system for additional medical procedures.
The Morrisville, North Carolina-based company’s Senhance surgical system can now be used for hernia and gallbladder removal surgeries.
There are approximately 760,000 inguinal hernia and 1.2 million gallbladder removal procedures performed annually in the United States.
“These expanded procedures are commonly performed at over 95 percent of hospitals in the United States,” said Chief Executive Officer Todd Pope in a statement. “We believe this indication expansion will significantly increase the applicability of Senhance to more institutions, particularly those with a busy general surgery practice.”
TransEnterix shares rose 28 cents, or 8.95 percent, to $3.41 on Tuesday after opening at $3.80.
In the United States, Senhance is now cleared for laparoscopic colorectal, gynecologic, inguinal hernia and cholecystectomy surgery.
The company received its first Food and Drug Administration approval in October. In the first quarter, it sold two Senhance units in international markets, and it has already sold three units in the second quarter, two of which were overseas.
Last week, the company agreed to a $40 million loan line that allowed it to refinance its debt.
This story is from the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism
